ClinicalTrials.gg
CompletedNCT07779044Updated Aug 27, 2026

Mindfulness-Based Cognitive Behavioral Program for People With Diabetes Mellitus

An interventional study of Mindfulness-Based Cognitive Behavioral Program in Diabetes Mellitus, Diabetes Mellitus ( Type 1 and Type 2) and Depressive Symptoms, sponsored by Center for Strategic Studies and Health Training, Syria. Completed at 1 site in Syria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Center for Strategic Studies and Health Training, Syria · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2025, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This randomized controlled trial evaluated the effectiveness of a mindfulness-based cognitive behavioral program in improving quality of life and glycemic control among adults with diabetes mellitus in Damascus, Syria. The intervention combined cognitive behavioral strategies and mindfulness practices and was delivered through 14 weekly sessions over approximately three months. Quality of life was assessed using the WHOQOL-BREF, and glycemic control was assessed using glycated hemoglobin (HbA1c) levels. The study compared participants receiving the intervention with a control group receiving routine diabetes care.

Read the detailed description

Diabetes mellitus is a chronic condition that requires continuous self-management and may negatively affect psychological well-being, quality of life, and glycemic control. Psychological distress and difficulties in coping with diabetes may interfere with self-care behaviors and disease management.

This randomized controlled trial was conducted to evaluate the effectiveness of an integrated mindfulness-based cognitive behavioral program among adults with diabetes mellitus in Damascus, Syria. The intervention was designed to address psychological and behavioral factors that may affect diabetes self-management. It combined cognitive behavioral techniques, including psychoeducation, cognitive restructuring, behavioral activation, and coping strategies, with mindfulness exercises, relaxation techniques, emotional regulation, and home practice.

A total of 40 participants completed the study, with 20 participants allocated to the intervention group and 20 to the control group. Eligible adults with type 1 or type 2 diabetes were randomly assigned to either the intervention group or the control group. Participants in the intervention group received 14 weekly counseling sessions over approximately three months, with each session lasting approximately 90 minutes. The control group received routine diabetes care without an additional psychological intervention.

Quality of life was assessed using the World Health Organization Quality of Life-Brief Version (WHOQOL-BREF), which evaluates physical health, psychological health, social relationships, and environmental domains. Glycemic control was assessed using glycated hemoglobin (HbA1c) measured before and after the intervention. The Beck Depression Inventory (BDI) was used during screening to identify participants with mild to moderate depressive symptoms and determine eligibility; it was not used as an outcome measure.

The study aimed to determine whether the integrated mindfulness-based cognitive behavioral program could improve quality of life and glycemic control compared with routine diabetes care

02

Conditions studied

  • Diabetes Mellitus
  • Diabetes Mellitus ( Type 1 and Type 2)
  • Depressive Symptoms

Keywords

  • Diabetes mellitus
  • Mindfulness
  • Cognitive Behavioral Therapy
  • Quality of Life
  • Glycated Hemoglobin
  • Randomized Controlled Trial.
  • Depression
03

In context

Diabetes Mellitus

8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

This is the only study on the registry with Center for Strategic Studies and Health Training, Syria as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-70 years.
  • Diagnosis of type 1 or type 2 diabetes mellitus.
  • Baseline level greater than 6.5%.
  • Mild to moderate depressive symptoms according to the Beck Depression - -Inventory (BDI).
  • Ability to understand the study procedures and intervention instructions.
  • Willingness to participate in all intervention sessions.
  • Ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • Severe psychiatric disorders requiring specialized psychiatric care.
  • Acute medical conditions that could prevent participation in the intervention.
  • Receiving regular psychotherapy or another similar psychological intervention.
  • Inability to understand the intervention instructions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Mindfulness-Based Cognitive Behavioral Intervention

    Participants received a structured mindfulness-based cognitive behavioral program consisting of 14 weekly sessions over approximately three months, in addition to routine diabetes care.

    Behavioral: Mindfulness-Based Cognitive Behavioral Program

  • No intervention
    Routine Diabetes Care (Control)

    Participants received routine diabetes care without any additional psychological or behavioral intervention during the study period.

Interventions

  • BehavioralMindfulness-Based Cognitive Behavioral Program

    Participants in the intervention group received a structured mindfulness-based cognitive behavioral program consisting of 14 weekly sessions delivered over approximately three months. Each session lasted approximately 90 minutes, including a 15-minute break. The program incorporated psychoeducation, cognitive restructuring, mindfulness exercises, behavioral activation, emotional regulation, relaxation techniques, coping strategies, and home practice assignments. The intervention was delivered by qualified mental health professionals in addition to routine diabetes care.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin (HbA1c) Level

    Change in HbA1c level from baseline to immediately after completion of the intervention.

    Time frame: Baseline and 3 months (post-intervention).

Secondary outcomes

  1. Within-group change in Quality of Life Measured by the World Health Organization Quality of Life-BREF (WHOQOL-BREF) Questionnaire

    Change in quality of life from baseline to 3 months (post-intervention), measured using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire within the intervention group. The questionnaire assesses four primary domains: Physical Health, Psychological Health, Social Relationships, and Environment, with domain scores ranging from 4 to 20, where higher scores indicate better quality of life. An overall quality of life index is also calculated on a scale of 0 to 100, with higher values reflecting superior general quality of life.

    Time frame: Baseline and 3 months (evaluated in the intervention arm).

07

Study locations

1 site
  • Center for Strategic Studies and Health Training
    Damascus, Damascus Governorate, Syria
08

References and documents

Publications

  • Winkley K, Upsher R, Stahl D, Pollard D, Brennan A, Heller SR, Ismail K. Psychological interventions to improve glycemic control in adults with type 2 diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2020 Apr;8(1):e001150. doi: 10.1136/bmjdrc-2019-001150. PubMed 32273289 ↗
  • Newby J, Robins L, Wilhelm K, Smith J, Fletcher T, Gillis I, Ma T, Finch A, Campbell L, Andrews G. Web-Based Cognitive Behavior Therapy for Depression in People With Diabetes Mellitus: A Randomized Controlled Trial. J Med Internet Res. 2017 May 15;19(5):e157. doi: 10.2196/jmir.7274. PubMed 28506956 ↗
  • Zarifsanaiey N, Jamalian K, Bazrafcan L, Keshavarzy F, Shahraki HR. The effects of mindfulness training on the level of happiness and blood sugar in diabetes patients. J Diabetes Metab Disord. 2020 Mar 2;19(1):311-317. doi: 10.1007/s40200-020-00510-7. eCollection 2020 Jun. PubMed 32550181 ↗
  • Yang X, Li Z, Sun J. Effects of Cognitive Behavioral Therapy-Based Intervention on Improving Glycaemic, Psychological, and Physiological Outcomes in Adult Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Front Psychiatry. 2020 Jul 28;11:711. doi: 10.3389/fpsyt.2020.00711. eCollection 2020. PubMed 32848906 ↗
  • Ni YX, Ma L, Li JP. Effects of mindfulness-based intervention on glycemic control and psychological outcomes in people with diabetes: A systematic review and meta-analysis. J Diabetes Investig. 2021 Jun;12(6):1092-1103. doi: 10.1111/jdi.13439. Epub 2020 Nov 22. PubMed 33064926 ↗
  • DiNardo MM, Greco C, Phares AD, Beyer NM, Youk AO, Obrosky DS, Morone NE, Owen JE, Saba SK, Suss SJ, Siminerio L. Effects of an integrated mindfulness intervention for veterans with diabetes distress: a randomized controlled trial. BMJ Open Diabetes Res Care. 2022 Mar;10(2):e002631. doi: 10.1136/bmjdrc-2021-002631. PubMed 35346971 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers because of privacy and confidentiality considerations and to protect the personal and health information of study participants.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jan 2026, 3 months.

Of 1,583 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 3 months is below that.

Counting every sponsor, half of 1,743 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 21, 2026
StartActual
Oct 26, 2025
Primary completionActual
Jan 30, 2026
CompletionActual
Jan 30, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07779044
Lead sponsor
Center for Strategic Studies and Health Training, Syria
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Oct 26, 2025
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Last update
Aug 27, 2026

Study contacts

ZaynALsham M AlQatrangi, BPharm, MPH
principal investigator · Center for Strategic Studies and Health Training

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion